Cullinan Therapeutics Inc (NASDAQ: CGEM) kicked off on Friday, down -9.41% from the previous trading day, before settling in for the closing price of $15.30. Over the past 52 weeks, CGEM has traded in a range of $7.64-$30.19.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -20.00% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 18.87%. With a float of $37.94 million, this company’s outstanding shares have now reached $42.90 million.
In an organization with 85 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cullinan Therapeutics Inc (CGEM) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cullinan Therapeutics Inc is 32.76%, while institutional ownership is 77.28%. The most recent insider transaction that took place on Nov 05 ’24, was worth 125,120. In this transaction Chief Scientific Officer of this company sold 8,000 shares at a rate of $15.64, taking the stock ownership to the 107,942 shares. Before that another transaction happened on Sep 05 ’24, when Company’s Chief Scientific Officer sold 8,000 for $18.09, making the entire transaction worth $144,720. This insider now owns 115,942 shares in total.
Cullinan Therapeutics Inc (CGEM) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.54 earnings per share (EPS), higher than consensus estimate (set at -0.98) by 0.44. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.84 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.87% per share during the next fiscal year.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
Take a look at Cullinan Therapeutics Inc’s (CGEM) current performance indicators. Last quarter, stock had a quick ratio of 24.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.88, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -3.09 in one year’s time.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
Let’s dig in a bit further. During the last 5-days, its volume was 0.78 million. That was better than the volume of 0.65 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 12.45%. Additionally, its Average True Range was 1.06.
During the past 100 days, Cullinan Therapeutics Inc’s (CGEM) raw stochastic average was set at 1.79%, which indicates a significant decrease from 3.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.00% in the past 14 days, which was higher than the 59.10% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.54, while its 200-day Moving Average is $18.52. However, in the short run, Cullinan Therapeutics Inc’s stock first resistance to watch stands at $15.00. Second resistance stands at $16.15. The third major resistance level sits at $16.78. If the price goes on to break the first support level at $13.22, it is likely to go to the next support level at $12.59. Assuming the price breaks the second support level, the third support level stands at $11.44.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Key Stats
The company with the Market Capitalisation of 731.07 million has total of 58,228K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -153,160 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -40,560 K.
